Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective

Axel F Grothey

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The administration of adjuvant chemotherapy after resection of stage III colon cancer to prolong disease-free survival (DFS) and increase overall survival (OS) has been clinical standard since the early 1990s. Recently, 3-year DFS was recognized as surrogate endpoint for OS based on a meta-analysis of trials utilizing 5-fluorouracil as only active chemotherapy component. The standard of care in adjuvant therapy, however, has moved on to modern combination regimens including oxaliplatin, and novel targeted agents such as angiogenesis inhibitors and antibodies against epidermal growth factor receptor are currently undergoing rigorous testing in phase III adjuvant trials. For the practicing clinician, the use of surrogate endpoints to appreciate the efficacy of a specific adjuvant therapy contains various challenges, in particular, in discussions with patients. It is questionable whether 3-year DFS can still be considered an appropriate predictor of OS in complex clinical scenarios with continuous change in treatment standards in the adjuvant and palliative situation. Thus, the practicing oncologist needs to be aware of the limitations in the definition of surrogate endpoints in the adjuvant setting.

Original languageEnglish (US)
Pages (from-to)529-535
Number of pages7
JournalStatistical Methods in Medical Research
Volume17
Issue number5
DOIs
StatePublished - 2008

Fingerprint

Surrogate Endpoint
Colorectal Cancer
Disease-Free Survival
Colorectal Neoplasms
oxaliplatin
Biomarkers
Survival
Angiogenesis Inhibitors
Chemotherapy
Adjuvant Chemotherapy
Standard of Care
Epidermal Growth Factor Receptor
Fluorouracil
Colonic Neoplasms
Therapy
Meta-Analysis
Therapeutics
Drug Therapy
Angiogenesis
Antibodies

ASJC Scopus subject areas

  • Statistics and Probability
  • Epidemiology
  • Health Information Management

Cite this

Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. / Grothey, Axel F.

In: Statistical Methods in Medical Research, Vol. 17, No. 5, 2008, p. 529-535.

Research output: Contribution to journalArticle

@article{f5031b0d977d42c0a1f33e8e5e75db48,
title = "Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective",
abstract = "The administration of adjuvant chemotherapy after resection of stage III colon cancer to prolong disease-free survival (DFS) and increase overall survival (OS) has been clinical standard since the early 1990s. Recently, 3-year DFS was recognized as surrogate endpoint for OS based on a meta-analysis of trials utilizing 5-fluorouracil as only active chemotherapy component. The standard of care in adjuvant therapy, however, has moved on to modern combination regimens including oxaliplatin, and novel targeted agents such as angiogenesis inhibitors and antibodies against epidermal growth factor receptor are currently undergoing rigorous testing in phase III adjuvant trials. For the practicing clinician, the use of surrogate endpoints to appreciate the efficacy of a specific adjuvant therapy contains various challenges, in particular, in discussions with patients. It is questionable whether 3-year DFS can still be considered an appropriate predictor of OS in complex clinical scenarios with continuous change in treatment standards in the adjuvant and palliative situation. Thus, the practicing oncologist needs to be aware of the limitations in the definition of surrogate endpoints in the adjuvant setting.",
author = "Grothey, {Axel F}",
year = "2008",
doi = "10.1177/0962280207081853",
language = "English (US)",
volume = "17",
pages = "529--535",
journal = "Statistical Methods in Medical Research",
issn = "0962-2802",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective

AU - Grothey, Axel F

PY - 2008

Y1 - 2008

N2 - The administration of adjuvant chemotherapy after resection of stage III colon cancer to prolong disease-free survival (DFS) and increase overall survival (OS) has been clinical standard since the early 1990s. Recently, 3-year DFS was recognized as surrogate endpoint for OS based on a meta-analysis of trials utilizing 5-fluorouracil as only active chemotherapy component. The standard of care in adjuvant therapy, however, has moved on to modern combination regimens including oxaliplatin, and novel targeted agents such as angiogenesis inhibitors and antibodies against epidermal growth factor receptor are currently undergoing rigorous testing in phase III adjuvant trials. For the practicing clinician, the use of surrogate endpoints to appreciate the efficacy of a specific adjuvant therapy contains various challenges, in particular, in discussions with patients. It is questionable whether 3-year DFS can still be considered an appropriate predictor of OS in complex clinical scenarios with continuous change in treatment standards in the adjuvant and palliative situation. Thus, the practicing oncologist needs to be aware of the limitations in the definition of surrogate endpoints in the adjuvant setting.

AB - The administration of adjuvant chemotherapy after resection of stage III colon cancer to prolong disease-free survival (DFS) and increase overall survival (OS) has been clinical standard since the early 1990s. Recently, 3-year DFS was recognized as surrogate endpoint for OS based on a meta-analysis of trials utilizing 5-fluorouracil as only active chemotherapy component. The standard of care in adjuvant therapy, however, has moved on to modern combination regimens including oxaliplatin, and novel targeted agents such as angiogenesis inhibitors and antibodies against epidermal growth factor receptor are currently undergoing rigorous testing in phase III adjuvant trials. For the practicing clinician, the use of surrogate endpoints to appreciate the efficacy of a specific adjuvant therapy contains various challenges, in particular, in discussions with patients. It is questionable whether 3-year DFS can still be considered an appropriate predictor of OS in complex clinical scenarios with continuous change in treatment standards in the adjuvant and palliative situation. Thus, the practicing oncologist needs to be aware of the limitations in the definition of surrogate endpoints in the adjuvant setting.

UR - http://www.scopus.com/inward/record.url?scp=52649088322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649088322&partnerID=8YFLogxK

U2 - 10.1177/0962280207081853

DO - 10.1177/0962280207081853

M3 - Article

C2 - 18285442

AN - SCOPUS:52649088322

VL - 17

SP - 529

EP - 535

JO - Statistical Methods in Medical Research

JF - Statistical Methods in Medical Research

SN - 0962-2802

IS - 5

ER -